Abstract
93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional Living Index – Cancer (FLIC) questionnaire. Pain response was measured using the Radiation Therapy Oncology Group scoring system. Overall there was limited QoL improvement over 3 months following Sr-89. However, in the 53 patients (63%) achieving pain responses, QoL did significantly improve within 6 weeks of receiving Sr-89 compared to patients with stable or worsening bone pain, and this was independent of other parameters that might influence QoL outcomes, such as performance status, baseline PSA and extent of skeletal disease (P = 0.004). PSA ‘response’ occurred in 30 patients (37%) over 4 months after Sr-89. This did not appear to correlate with clinical improvement. This study supports the presumption that improvement in pain following Sr-89 is accompanied by better QoL. The lack of correlation of PSA response and clinical parameters indicates that in the palliative setting, PSA may not provide a useful surrogate for treatment outcome. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Kaplan EL and Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan JB, MacLeod PM and Zivanovic MA (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Brit J Radio 64: 816–822
Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, MacLeod PM, Porter AT and Zivanovic MA (1991) A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Euro J Cancer 27: 954–958
Malmberg I, Persson U, Ask A, Tennvall J and Abrahamsson PA (1997) Painful bone metastases in hormone-refractory prostate cancer: Economic costs of Strontium-89 and/or external radiotherapy. Urology 50: 747–753
McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA and Porter AT (1994) A retrospective analysis of the cost effectiveness of treatment with Metastron® (89 Sr-chloride) in patients with prostate cancer metastatic to bone. Nuclear Medicine Communications 15: 499–504
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Porter AT and McEwan AJB (1993) Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomised controlled trial. Seminars in Oncology 20: 38–43
Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C and Yardley J (1993) Results of a randomised phase-III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology Biology Phys 25: 805–813
Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NSE, Russell JM and Yardley J (1994) A comparison of the palliative effects of Strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology 31: 33–40
Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, Wegst AV and Ackery DM (1989) Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9: 271–281
Schipper H, Clinch J, McMurray A and Levitt M (1984) Measuring the Quality of life of cancer patients: the functional living index – cancer: development and validation. Journal of Clinical Oncology 2: 472–483
Tong D, Gillick L and Hendrickson R (1982) The palliation of symptomatic osseous metastases. Final results of the study of the Radiation Therapy Oncology Group. Cancer 50: 893–899
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Turner, S., Gruenewald, S., Spry, N. et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84, 297–302 (2001). https://doi.org/10.1054/bjoc.2000.1610
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1610
Keywords
This article is cited by
-
Association of Urinary Strontium with Cardiovascular Disease Among the US Adults: A Cross-Sectional Analysis of the National Health and Nutrition Examination Survey
Biological Trace Element Research (2023)
-
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
European Journal of Nuclear Medicine and Molecular Imaging (2018)
-
Burden of skeletal-related events in prostate cancer: unmet need in pain improvement
Supportive Care in Cancer (2015)
-
Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases
International Journal of Clinical Oncology (2014)
-
Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival
Annals of Nuclear Medicine (2014)